BA28EC2F-5186-4DED-8814-5F0464AB8B87
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 23.71879106438896
- age_years
- 63
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.721
- INTERFERON_GAMMA_RESPONSE+0.636
- IL6_JAK_STAT3_SIGNALING+0.488
- ALLOGRAFT_REJECTION+0.446
- OXIDATIVE_PHOSPHORYLATION+0.410
- INFLAMMATORY_RESPONSE+0.393
- APOPTOSIS+0.379
- MTORC1_SIGNALING+0.360
- IL2_STAT5_SIGNALING+0.359
- UNFOLDED_PROTEIN_RESPONSE+0.358
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.351
- SPERMATOGENESIS-0.330
- KRAS_SIGNALING_DN-0.255
- MYOGENESIS-0.176
- WNT_BETA_CATENIN_SIGNALING-0.119
- HEDGEHOG_SIGNALING-0.067
- APICAL_JUNCTION-0.062
- ESTROGEN_RESPONSE_LATE-0.022
- UV_RESPONSE_UP+0.000
- APICAL_SURFACE+0.053
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.941 |
| 2 | 385ECC71-2BF4-4E14-B2CC-8423E79BDEBE | — | — | 0.934 |
| 3 | 8CDEDFEC-954A-4D01-AF6B-AF55CFE5FEAB | — | — | 0.932 |
| 4 | SRR934897 | — | — | 0.930 |
| 5 | 311D796C-BDD1-4C6B-9FD4-A053778AE1BB | — | — | 0.929 |
| 6 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.928 |
| 7 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.928 |
| 8 | F42071CA-8794-4C79-8B02-8D48C70E8BA1 | — | — | 0.928 |
| 9 | SRR934921 | — | — | 0.927 |
| 10 | EC7327B2-6767-4005-9C51-005957C1F923 | — | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.721 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.636 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.488 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.446 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.393 | Idelalisib | — uncovered |
| APOPTOSIS | 0.379 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.359 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.358 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.357 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.353 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.343 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.318 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.314 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.299 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.295 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.287 | Inavolisib | — uncovered |